Table 1.

Patient characteristics and outcome of treatments based on xenograft predictions

Identification numberGenderAge (years)TumorXenograftPrior systemic therapySystemic therapy administered on the basis of xenograft dataResponseDuration of response (months)
JH033Male63Pancreatic ductal adenocarcinomaPrimary tumorGemcitabineMitomycin C, cisplatinPR50+
JH082Female64Pancreatic ductal adenocarcinomaPrimary tumorNoneGemcitabineProgressive disease
JH102Female66Pancreatic ductal adenocarcinomaPrimary tumorNoneGemcitabineStable disease
JH161Female70Pancreatic ductal adenocarcinomaPrimary tumorNoneGemcitabineStable disease
CBI-0601Female55LeiomyosarcomaPelvic metastasisAdriamycin, ifosfamideGemcitabine, docetaxel, bevacizumabPR9
Gemcitabine, doxetaxelCapcetabine, temozlomidePR9
CBI-0602Male45Mesenchymalchondro sarcomaLung mestastasisVACDocetaxel, irinotecan, bevacizumabPR9
SunitinibStable disease4
CBI-0603Male50Non–small cell lung carcinomaPrimary tumorCarboplatin, paclitaxelSorafenib, irinotecan, bevacizumabPR9
PemetrexedNo response
CBI-0701Male36MyoepitheliomaPrimary tumorNoneDoxorubicin, cisplatinProgressive disease
ImatinibProgressive disease
Carboplatin-bevacizumabProgressive disease
CBI-0803Male54Esophageal adenocarcinomaLiver metastasisEpirubicin, 5-fluorouracil, cisplatinIrinotecan-cetuximab- bevacizumabPR14
Abraxane-avastinPR9
Ixabepilone-avastinPR9
Ixabepilone-navelbinePR6+
CBI-0805Female44Colon adenocarcinomaLiver metastasisFOLFOXIrinotecanPR14
Capecitabine, lapatanibPR6+
CBI-0810Female36Breast cancerLiver metastasis5-fluorouracil, cyclophosphamiirinotecan, bevacizumabNoneNo response
No response
CBI-0901Male49RhabdomyosarcomaLung metastasisNoneDocetaxel, gemcitabine, bevacizumabPR8
CBI-0907Female62ColonLiver metstasisFOLFOXCetuximab, irinotecanPR6
IrinotecanPR15
CBI-0914Male58MelanomaLung metastasisNoneB-raf inhibitorPR6

Note: When tumorgrafts reached approximately 150 mm3, animals were randomized (5 mice with tumors on both flanks per group) and dosing initiated. Details on drugs, doses, and schedules are provided in Supplementary Table S1.

Abbreviations: VAC, vinblastine, doxorubicin and cisplatin; FOLFOX, folinic acid, 5-fluorouracil, oxaliplatin.